Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P
Open Access
- 28 August 2021
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 297 (4) , 101136
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Advances in the assessment and control of the effector functions of therapeutic antibodiesNature Reviews Drug Discovery, 2011
- Antibodies to human serum amyloid P component eliminate visceral amyloid depositsNature, 2010
- New insights into the molecular mechanisms of classical complement activationMolecular Immunology, 2010
- The tick-over theory revisited: Formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb)Molecular Immunology, 2008
- Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surfaceBiomaterials, 2005
- Effect of complement inhibition and heparin coating on artificial surface–induced leukocyte and platelet activationThe Annals of Thoracic Surgery, 2004
- Structure of pentameric human serum amyloid P componentNature, 1994
- Structure-function relationships in the inhibitory effect of heparin on complement activation: Independency of the anti-coagulant and anti-complementary sites on the heparin moleculeMolecular Immunology, 1988
- Reaction between the isolated globular sub-units of the complement component Clq and IgG-complexesMolecular Immunology, 1979
- Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidaseJournal of Clinical Investigation, 1970